Diffuse large B-cell lymphoma recurrent
Not recruitingStudy of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients
Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients
- Disease:Diffuse large B-cell lymphoma recurrent
- Substances:MosunetuzumabPolatuzumab Vedotin+1
Spain- Participants:18–64 years · 65+ years
- Substances:Mosunetuzumab
- Sponsor:F. Hoffmann-La Roche AG











